23 November 2020
\n \n \n \nMultiple recent case reports have suggested a link between COVID-19 and Guillain-Barre\u0301 syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.
\n \n\n \n \n20 November 2020
\n \n \n \nNew research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.
\n \n\n \n \n5 November 2020
\n \n \n \n2020\u2019s Emerging Leaders Prize awards \u00a3200,000 to outstanding scientists from the University of Oxford, University College London and King\u2019s College London, who are all working in the field of pain research.
\n \n\n \n \n15 October 2020
\n \n \n \nNeuropathic pain arises from disease or damage of the nervous system. It is a major clinical problem affecting 5-10% of the adult population, despite the use of current therapies.
\n \n\n \n \n28 September 2020
\n \n \n \n\n \n \n27 September 2020
\n \n \n \nThe largest research grant ever given for neurodevelopmental conditions has been awarded by the Innovative Medicines Initiative to an international consortium academically led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King\u2019s College London.
\n \n\n \n \n22 September 2020
\n \n \n \nCongratulations to our MSc in Clinical and Therapeutic Neuroscience, Class of 2019/20 for successfully completing the course.
\n \n\n \n \n14 September 2020
\n \n \n \n\n \n \n7 September 2020
\n \n \n \nIn a new study, neuroscientists have found that raised blood pressure and diabetes in mid-life alter brain structure to slow thinking speed and memory.
\n \n\n \n \n28 July 2020
\n \n \n \nThe Medical Research Council has awarded Alexander Thompson a prestigious five-year Lady Edith Wolfson MRC Clinician Scientist Fellowship to investigate the causes of amyotrophic lateral sclerosis (ALS, also known as motor neuron disease, MND).
\n \n\n \n \n20 July 2020
\n \n \n \n\n \n \n13 May 2020
\n \n \n \nThe Academy of Medical Sciences has today announced the election of fifty new Fellows, including Professor David Bennett and Professor Peter Brown.
\n \n\n \n \n30 April 2020
\n \n \n \nNDCN researchers lead a global study based on analysing survey data
\n \n\n \n \n14 April 2020
\n \n \n \nResearch carried out by George Tofaris and his team has led to the development of a new way to test for Parkinson\u2019s disease before the main symptoms occur. This could allow clinicians to identify patients who would benefit from precision therapies that are currently at clinical trial stage.
\n \n\n \n \n6 April 2020
\n \n \n \nDr Alexander Davies summarises a departmental seminar by Dr Simon Rinaldi
\n \n\n \n \n11 February 2020
\n \n \n \nThe NIHR Research and Innovation for Global Health Transformation (RIGHT) programme has awarded \u00a34.9 million to help fund a project investigating epilepsy in sub-Saharan Africa.
\n \n\n \n \n17 January 2020
\n \n \n \nDr Arjune Sen is leading a new six-month trial funded by the MRC Confidence in Concept scheme. The study is known as IliAD (Investigation of Levetiracetam in Alzheimer's Disease).
\n \n\n \n \n18 December 2019
\n \n \n \nThe Oxford Parkinson's Disease Centre received the award for their contribution to the Critical Path for Parkinson\u2019s initiative
\n \n\n \n \n17 December 2019
\n \n \n \nEmeritus Professor Angela Vincent received the Research Recognition Award, clinical science, at the annual meeting of the American Epilepsy Society.
\n \n\n \n \n11 November 2019
\n \n \n \nNDCN\u2019s Associate Professor Andrea Nemeth is leading the Oxford part of a clinical trial for Hungtinton\u2019s disease.
\n \n\n \n \n